Curious about all the patents and trade secrets behind the technology of C19 injections?

Check this out from May 2021.

A network analysis of COVID-19 mRNA vaccine patents | Nature Biotechnology

https://www.nature.com/articles/s41587-021-00912-9

I have extracted a few salient points that reveal all the parties involved.

You might be interested in the missing bits, so read the full article if you want more detail and precision.

“..a series of sublicenses for mRNA-related patents that stem from the University of Pennsylvania to both Moderna and BioNTech7,8,9. The 2017 filings indicate that the University of Pennsylvania exclusively licensed their patents to mRNA RiboTherapeutics, which then sublicensed them to its affiliate CellScript. CellScript proceeded to sublicense the patents to Moderna and BioNTech;”

“..early work on lipid nanoparticles was done jointly by the University of British Columbia and Arbutus Biopharmaceuticals in 1998. SEC filings show that patents relating to this early technology were solely assigned to the University of British Columbia and then licensed back to Arbutus10. Further analysis reveals that in 2012 Arbutus licensed a set of patents relating to the delivery of nucleic acids to Acuitas Therapeutics. In 2016, Acuitas entered into a development and option agreement with CureVac,”

“..Arbutus also entered into an agreement with Roivant to spin out Genevant, which received a license for the patent portfolio on lipid nanoparticles13. Genevant sublicensed the patents to BioNTech, who then entered into an agreement with Pfizer to develop a COVID-19 vaccine14,15,16. It is also important to note that the US National Institutes of Health (NIH) and Moderna entered into an agreement in 2019 to co-develop coronavirus vaccines; however, this was before the identification and spread of SARS-CoV-217,18.”

Here is a visual of all the entangled particles!

All clear now? Haha!

I suspect there is a wealth of information in the 23 references at the bottom of the “nature.com” article here:

https://citation-needed.springer.com/v2/references/10.1038/s41587-021-00912-9?format=refman&flavour=references